Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2018
19th World Conference on Lung Cancer
Access to all presentations that occur during the 19th World Conference on Lung Cancer in Toronto, ON
Presentation Date(s):- Sept 23 - 26, 2018
- Total Presentations: 2384
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Presentations will be available 24 hours after their live presentation time
-
+
JCSE01 - Perspectives for Lung Cancer Early Detection
- Type: Joint IASLC/CSCO/CAALC Session
- Track: Screening and Early Detection
- Presentations: 24
- Coordinates: 9/23/2018, 07:30 - 11:15, Room 202 BD
-
+
JCSE01.10 - A Ph3 Study of Niraparib as Maintenance Therapy in 1L Platinum Responsive Extensive Disease Small Cell Lung Cancer Patients
10:25 - 10:35 | Presenter: Shun Lu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
JCSE01.16 - Positive Correlation Between Whole Genomic Copy Number Variant Scoring and the Grading System in Lung Non-Mucinous Invasive Adenocarcinoma
11:15 - 11:15 | Presenter: Zheng Wang
- Abstract
Loading... -
+
JCSE01.22a - Tislelizumab Combined With Chemotherapy as First-Line Treatment in Chinese Patients With Advanced Lung Cancer
11:15 - 11:15 | Author(s): Jun Zhao
- Abstract
No abstract available for this presentation
-
+
MTE01 - Preclinical Models of Lung Cancer (Ticketed Session)
- Type: Meet the Expert Session
- Track: Biology
- Presentations: 2
- Coordinates: 9/24/2018, 07:00 - 08:00, Room 206 F
-
+
MTE01.02 - Lung Patient Derived Xenograft and Organoid
07:30 - 08:00 | Presenter: Nadeem Moghal
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA01 - Early Stage Lung Cancer: Questions and Controversies
- Type: Mini Oral Abstract Session
- Track: Treatment of Early Stage/Localized Disease
- Presentations: 12
- Coordinates: 9/24/2018, 10:30 - 12:00, Room 202 BD
-
+
MA01.05 - Opioids and Sleep Medication Use After Surgery for Early Stage Lung Cancer: A SEER-Medicare Analysis
11:00 - 11:05 | Presenter: Stephanie Tuminello
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA02 - Improving Outcomes for Patients with Lung Cancer
- Type: Mini Oral Abstract Session
- Track: Advanced NSCLC
- Presentations: 12
- Coordinates: 9/24/2018, 10:30 - 12:00, Room 201 BD
-
+
MA02.01 - ROS1 Gene Rearrangements Are Associated with an Exaggerated Risk of Peri-Diagnosis Thromboembolic Events
10:30 - 10:35 | Presenter: Terry L. Ng
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA05 - Improving Outcomes in Locoregional NSCLC II
- Type: Mini Oral Abstract Session
- Track: Treatment of Locoregional Disease - NSCLC
- Presentations: 12
- Coordinates: 9/24/2018, 13:30 - 15:00, Room 105
-
+
MA05.01 - E6508: Phase II Study of Immunotherapy with Tecemotide and Bevacizumab after Chemoradiation in Unresectable Stage III NS-NSCLC
13:30 - 13:35 | Presenter: Jyoti Patel
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
OA07 - Oligometastasis: What Should Be the State-Of-The-Art?
- Type: Oral Abstract Session
- Track: Oligometastatic NSCLC
- Presentations: 8
- Coordinates: 9/24/2018, 15:15 - 16:45, Room 107
-
+
OA07.05 - Local Ablative Therapy Improves Survival in Patients with Synchronous Oligometastatic NSCLC Harboring EGFR Mutation Treated with EGFR-TKIs
16:00 - 16:10 | Author(s): Qinghua Xu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P1.01 - Advanced NSCLC (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 112
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.01-39 - Cost-Effectiveness of Crizotinib Versus Chemotherapy as First-Line Treatment of ALK Positive Advanced NSCLC -- A Real World Study
16:45 - 18:00 | Presenter: Meijuan Huang
- Abstract
Loading... -
+
P1.01-42 - Real-World Evaluation of Tolerability in Older Adult Patients (≥75 Years Old) with EGFR-mutated NSCLC
16:45 - 18:00 | Presenter: Shirley Xue Jiang
- Abstract
Loading... -
+
P1.01-47 - Phase I/II Trial of Dasatinib and Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
16:45 - 18:00 | Presenter: Chul Kim
- Abstract
Loading... -
+
P1.01-58 - Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers
16:45 - 18:00 | Presenter: Naixin Liang
- Abstract
Loading... -
+
P1.01-61 - Clinical Characterization of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes to Afatinib in Chinese Lung Cancers
16:45 - 18:00 | Author(s): Yi Hu
- Abstract
Loading... -
+
P1.01-86 - BTCRC-LUN15-017: Phase-Ib Study of Imprime PGG and Pembrolizumab in Stage IV NSCLC after Progression on Platinum Based Therapy
16:45 - 18:00 | Presenter: Ardaman Shergill
- Abstract
Loading... -
+
P1.01-90 - A Pilot Trial Assessing Apatinib Combined with Docetaxel (DTX) as Second-Line Chemotherapy for EGFR Negative Advanced NSCLC)
16:45 - 18:00 | Author(s): Tang Feng Lv
- Abstract
Loading... -
+
P1.01-95 - Crizotinib Treatment in 29 Advanced NSCLC Chinese Patients with ROS1 Rearrangement——A Single Chinese Cancer Institute Experience
16:45 - 18:00 | Author(s): Chang Liu
- Abstract
Loading... -
+
P1.01-96 - Concurrent ALK/EGFR Alterations in Chinese Lung Cancers: Frequency, Clinical Features, and Differential Response to Therapy
16:45 - 18:00 | Presenter: Da Wu
- Abstract
Loading... -
+
P1.01-98 - A Phase IIIb Trial of Afatinib in EGFRm+ NSCLC: Analyses of Outcomes in Patients with Brain Metastases or Dose Reductions
16:45 - 18:00 | Presenter: Yi-Long Wu
- Abstract
Loading... -
+
P1.01-99 - Detecting HER2 Alterations by Next Generation Sequencing (NGS) in Patients with Advanced NSCLC from the United States and China
16:45 - 18:00 | Presenter: Chong-Rui Xu
- Abstract
Loading... -
+
P1.01-103 - Leukocyte Telomere Length as a Novel Biomarker in Advanced Lung Adenocarcinoma Patients Treated with Gefitinib
16:45 - 18:00 | Presenter: Ming Yang
- Abstract
Loading... -
+
P1.01-112 - Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC
16:45 - 18:00 | Presenter: Caicun Zhou
- Abstract
Loading...
-
+
P1.03 - Biology (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 34
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.03-11 - Analysis of T-Cell Repertoires in Benign and Malignant Solitary Pulmonary Nodules to Evaluate Tumor Immune Microenviroment
16:45 - 18:00 | Presenter: Min Li
- Abstract
Loading... -
+
P1.03-14 - Interaction Between Celecoxib and Cisplatin is Dependent on The p53 Status in Human NSCLC Cell Lines
16:45 - 18:00 | Author(s): Mei Jiang
- Abstract
Loading... -
+
P1.03-15 - TMS Reduced Gefitinib Resistance In NSCLCs Via Suppressing MAPK/Akt/Bcl-2 Pathway by Upregulation of miR-345 and miR-498
16:45 - 18:00 | Presenter: Ping Liu
- Abstract
Loading...
-
+
P1.04 - Immunooncology (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 36
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.04-02 - Targeting Established Lung Cancer Through Combination of DNT Cellular Therapy with PD1 Checkpoint Blockade
16:45 - 18:00 | Presenter: Linan Fang
- Abstract
Loading... -
+
P1.04-04 - Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity
16:45 - 18:00 | Author(s): Chen-Yi Chiang
- Abstract
Loading... -
+
P1.04-36 - Tislelizumab Combined With Chemotherapy as First-Line Treatment in Chinese Patients With Advanced Lung Cancer
16:45 - 18:00 | Author(s): Jun Zhao
- Abstract
Loading...
-
+
P1.05 - Interventional Diagnostics/Pulmonology (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 23
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.05-09 - Dielectric Property Test for the Rapid Differential Diagnosis of Lung Nodules/Mass
16:45 - 18:00 | Presenter: Di Lu
- Abstract
Loading...
